Showing 1211-1220 of 21420 results for "".
- Oral PCSK9 Inhibitor Enlicitide Lowers LDL Cholesterol In Phase 3 Trialhttps://reachmd.com/news/oral-pcsk9-inhibitor-enlicitide-lowers-ldl-cholesterol-in-phase-3-trial/2487434/Key Takeaways Enlicitide was associated with a marked week 24 LDL cholesterol reduction, while placebo showed little change over the same interval. Week 52 LDL cholesterol and week 24 non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) also favor
- Multicomponent Maternal Sepsis Program Lowers Infection Eventshttps://reachmd.com/news/multicomponent-maternal-sepsis-program-lowers-infection-events/2487425/Key Takeaways The APT-Sepsis program was associated with a lower rate of the primary composite maternal infection outcome than usual care. The reported effect was generally similar across both countries and facility sizes and was described as sustained
- Whole Health Team Improved Pain Interference In VA Trialhttps://reachmd.com/news/whole-health-pain-interference-va/2487415/Key Takeaways The Whole Health arm was associated with greater improvement in 12-month pain interference than either comparator. Group cognitive behavioral therapy was not significantly different from usual care on the primary endpoint. Suicid
- Telitacicept Interim Phase 3 Trial in IgA Nephropathyhttps://reachmd.com/news/telitacicept-iga-nephropathy/2487417/Key Takeaways Telitacicept was associated with a larger reduction in proteinuria than placebo at the interim 39-week assessment. Estimated glomerular filtration rate declined less with telitacicept than with placebo over the reported follow-up.
- Tumor-Informed ctDNA Stratifies Risk in Anal Squamous Cell Carcinomahttps://reachmd.com/news/tumor-informed-ctdna-stratifies-risk-in-anal-squamous-cell-carcinoma/2487405/Key Takeaways End-of-treatment ctDNA positivity was associated with worse 1-year overall survival, progression-free survival, and locoregional failure, including 96% versus 63% overall survival and 92% versus 44% progression-free survival for ctDNA-negative ver
- MenACYW-TT Coadministration Trial Reports Non-Inferior Immune Responseshttps://reachmd.com/news/menacyw-tt-coadministration-trial-reports-non-inferior-immune-responses/2487412/Key Takeaways Both co-primary non-inferiority endpoints were met at the prespecified 6-month and 12- to 15-month assessments. Routine pediatric vaccine responses were also non-inferior with MenACYW-TT coadministration. Reactogenicity and broad
- Buprenorphine After Ketamine for Suicidal Ideation in MDDhttps://reachmd.com/news/buprenorphine-ketamine-suicidal-ideation-mdd/2487395/Key Takeaways Greater improvement in SSI total score was observed with buprenorphine than with placebo after ketamine. Depression scores did not differ significantly between groups. No serious treatment-related adverse events were reported.
- Thrive Trial Shows Increase in Home Health Referrals for Medicaid Patientshttps://reachmd.com/news/thrive-home-health-referrals-medicaid/2487391/Key Takeaways Trained discharge planners were more likely to refer eligible patients to home health services than planners who had not yet entered the intervention. Implementation ratings were uniformly high, with acceptability, appropriateness, and fe
- Maternal RSV Vaccination, Nirsevimab in Infants, and Sequential Administrationhttps://reachmd.com/news/maternal-rsv-infant-nirsevimab/2487394/Key Takeaways A prospective randomized phase 4 comparison examined maternal vaccination, infant nirsevimab, and sequential administration in enrolled mother-infant pairs. No related serious adverse events were seen in mothers or infants, and infant nir
- Ultra-Processed Food Intake and Mortality in the PLCO Cohorthttps://reachmd.com/news/ultra-processed-food-intake-and-mortality-in-the-plco-cohort/2487360/Key Takeaways Higher ultra-processed food intake was associated with modestly higher all-cause mortality in this cohort. Higher risks were also observed for circulatory system, nervous system, and other-cause mortality, while cancer mortality was not a